Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 5, 2005, Pages 1302-1306

  Kowalska, Elzbieta ^a   Narod, Steven A ^b,c   Huzarski, Tomasz ^a   Zajaczek, Stanislaw ^a   Huzarska, Jowita ^a   Gorski, Bohdan ^a   Lubinski, Jan ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DOUBLE STRANDED DNA; SELENIUM;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CHROMOSOME BREAKAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DIET SUPPLEMENTATION; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; LYMPHOCYTE CULTURE; ONCOGENE; OVARY CANCER; PHENOTYPE; POLAND; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIOXIDANTS; BLEOMYCIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; CHROMOSOME BREAKAGE; DIETARY SUPPLEMENTS; DNA DAMAGE; FEMALE; GENES, BRCA1; HUMANS; MIDDLE AGED; MUTAGENICITY TESTS; POLAND; SODIUM SELENITE;

EID: 18544389391     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-03-0448     Document Type: Article

References (34)

1. Ford D, Easton DF, Statton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE; Breast Cancer Linkage Consortium. Risks of cancer in BRCA1 mutation carriers. Lancet 1994;343:692-95.
3. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
4. 2-M cell cycle checkpoint induce generic instability in BRCA1 exon11 isoform deficient cells. Mol Cell 1999;3:389-95.
5. Tirkkonen M, Johannsson O, Agnarsson BA, et al. 1997 Distinct somatic genetic changes associated with tumour progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:1222-7.
6. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002;32:180-4.
7. Bai I, Fan S, Meng Q, et al. BRCA1 induces gene expression and resistance to oxidative stress. Cancer Res 2004;64:7893-909.
8. Seo YR, Kelly MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci 2002;99:14548-53.
9. Hsu TC, Johnston DA, Cherry LM, et al. Sensitivity to the genotoxic effects of bleomycin in humans; possible relationship to environmental carcinogenesis. Int J Cancer 1989;43:403-9.
10. Hsu TC, Cherry LM, Samaan N. Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet Cytogenet 1985;17:307-3.
11. Gu J, Bondy ML, Sigurdson A, Spitz MR, Hsu TC, Wu X. Three measures of mutagen sensitivity in a cancer-free population. Cancer Genet Cytogenet 1999;110:65-9.
12. Roy SK, Trivedi AH, Bakshi SR, et al. Bleomycin-induced chromosome damage in lymphocytes indicates inefficient DNA repair capacity in breast cancer families. J Exp Clin Cancer Res 2000;19:169-3.
13. Scott D, Spreadborough A, Levine E, Roberts SA. Genetic predisposition in breast cancer. Lancet 1994;344:1444.
14. Barrios L, Caballin MR, Miro R, et al. Chromosomal instability in breast cancer patients. Hum Genet 1991;88:39-41.
15. Liehr J. Is estradiol a genotoxic mutagenic carcinogen? Endocrin Rev 2000;156:1841-8.
16. Hagmar L, Brogger A, Hansteen IL, et al. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 1994;54:2919-22.
17. Schantz SP, Spitz MR, Hsu TC. Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst 1990;82:1773-75.
18. Spitz MR, Fueger JJ, Halabi S, et al. Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 1990;2:329-33.
19. Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1994;86:1681-4.
20. Spitz MR, Wu X, Jiang H, Hsu TC. Mutagen sensitivity as a marker of cancer susceptibility. J Cell Biochem 1996;25S:80-4.
21. Wu X, Gu J, Patt Y, et al. Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998;7:567-70.
22. Cloos J, Lemans CR, van der Sterre ML, Kuik DJ, Snow GB, Braal BJ. Mutagen sensitivity as a biomarker for second primary tumours after head and neck squamous cell carcinoma Cancer Epidemiol Biomarkers Prev 2000;9:713-7.
23. Clark LC, Combs GF, Turnbull BVV, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized control trial. Nutritional Prevention of Cancer Study Group. J Am Med Assoc 1996;276:1957-63.
24. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11:630-9.
25. Hunter DJ, Morris JS, Stampfer MJ, Colditz GA, Speizer FE, Willett WC. A prospective study of selenium status and breast cancer risk. J Am Med Assoc 1990;264:1128-31.
26. CHEK2 Breast Cancer Case-Control Consortium. CHEK2 1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74:1175-82.
27. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
28. Gorski B, Debniak T, Masojc B, et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 2003;106:379-81.
29. Chenevix-Trench G, Spurdle AB, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002;94:205-15.
30. Rodriguez-Lopez, Osorio A, Ribas G, et al. The variant E233G of the RAD51D gene could be low penetrance allele in high-risk breast cancer families without BRCA1 mutations. Int J Cancer 2004;110:845-9.
31. Liu JZ, Gilbert K, Parker HM, Haschek WM, Milner JA. Inhibition of 7,12-dimethlybenz(a)anthracene-induced mammary tumors and DNA adducts by dietary selenite. Cancer Res 1991;51:4613-7.
32. WHO. Vitamin and mineral requirement in human nutrition. Geneva: WHO; 2004.
33. Foray N, Randrianarison V, Marot D, Perricaudet M, Lenoir G, Feunteun J. γ-Rays induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene 1999;18:7334-42.
34. Nieuwenhuis B, Van Assen-Bolt AJ, Van Waarde-Verhage MAWH, et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol 2002;78:285-95.